OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mell Discusses Flaws in Risk Stratification for Head and Neck Cancer

February 26th 2018

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses flaws in the current model of risk stratification for patients with head and neck cancer.

Dr. Andtbacka Discusses the Role of T-VEC in Melanoma

February 24th 2018

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.

Dr. Portnoy on the Importance of Driver Mutations in the Treatment of NSCLC

February 24th 2018

David C. Portnoy, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of driver mutations in the treatment of non–small cell lung cancer (NSCLC).

Dr. Berdeja Discusses the Future of Treatment for Myeloma

February 24th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

Dr. Grupka on Mutations in Patients With Myelodysplastic Syndrome

February 24th 2018

Nichon L. Grupka, MD, pathologist, Novant Health Thomasville Medical Center, discusses the manifestations of mutations in myelodysplastic syndrome (MDS).

Dr. Bachier on the Evolution of Stem Cell Transplants in Hematologic Malignancies

February 24th 2018

Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses the advancement of supportive care in hematologic malignancies.

Dr. Moore Discusses Combinations in Ovarian Cancer

February 23rd 2018

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations in the treatment of patients with ovarian cancer.

Dr. West on the Future of Treatment for Patients With Gynecologic Malignancies

February 23rd 2018

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the future of treatment for patients with gynecologic malignancies.

Dr. Slovin Discusses GnRH Antagonists Versus Agonists

February 23rd 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the difference between GnRH antagonists and GnRH agonists.

Dr. McKay on Unmet Needs for RCC

February 23rd 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses unmet needs for patients with renal cell carcinoma (RCC).

Dr. Bekaii-Saab on the Impact of Regorafenib in CRC

February 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of regorafenib (Stivarga) on the treatment of patients with colorectal cancer (CRC).

Dr. Perl Discusses Upcoming CAR T-Cell Therapies for ALL

February 23rd 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses upcoming chimeric antigen receptor (CAR) T-cell therapies for patients with acute lymphoblastic leukemia (ALL).

Dr. Kambhampati on Venetoclax in Patients With Myeloid Malignancies

February 23rd 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Cancer Institute, discusses the impact of single-agent venetoclax (Venclexta) in patients with myeloid malignancies.

Dr. Donnellan on Developing Combinations in AML

February 23rd 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations in light of newly FDA-approved agents in acute myeloid leukemia (AML).

Dr. Mason on the Reliability of the PD-L1 Biomarker

February 22nd 2018

David P. Mason, MD, chief, Thoracic Surgery and Lung Transplantation, Baylor Scott & White Center for Thoracic Surgery, discusses the reliability of the PD-L1 biomarker in non–small cell lung cancer (NSCLC) and its potential applications in surgical approaches.

Dr. Konduri Addresses Unanswered Questions in NSCLC

February 22nd 2018

Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses lingering questions in patients with non–small cell lung cancer (NSCLC).

Dr. Chau on Analysis of Asian and Western Patients With Gastric/GEJ Cancer

February 22nd 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses an analysis of Asian and Western patients with chemotherapy-refractory gastric/gastroesophageal junction (GEJ) cancer.

Dr. Wise Discusses Challenges With Immunotherapy in Prostate Cancer

February 22nd 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses challenges with immunotherapy in prostate cancer.

Dr. Borgen Discusses HER2 Blockade in Breast Cancer

February 22nd 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

Dr. Bauml on HPV Vaccination for Head and Neck Cancer

February 22nd 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses HPV vaccination for patients with HPV-related head and neck cancer.